VistaGen Therapeutics, Inc.
VTGN
Positions held
Your positionsVTGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $10.93M | Enterprise value | -$20.02M | Trailing P/E | — | Forward P/E | -0.16 |
| PEG | — | Price / book | 0.45 | Beta | 0.33 | Dividend yield | 0.00% |
| Revenue growth | 5.0% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -9.0% |
| Profit margin | 0.0% | ROE | -1.7% | ROA | -83.2% | Debt / equity | 0.03 |
| Current ratio | 3.07 | Free cash flow | -$36.95M | Analyst recommendation | none | Mean target | $1.00 |
| 52w high | $5.14 | 52w low | $0.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $0.5M | $0.3M | $0.3M | $0.2M |
| Op margin | -904.3% | -3595.1% | -6450.8% | -7772.5% | -6477.0% |
| Net income | -$13.0M | -$16.3M | -$18.9M | -$19.4M | -$15.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$13.3M | -$16.7M | -$19.5M | -$20.1M | -$15.8M |
- Revenue +217% vs prior quarter ($1.5M vs $0.5M).
- Operating margin expanded to -904.3%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $0.5M | $1.1M | -$0.2M | — |
| Op margin | -5683.7% | -11517.1% | -3103.5% | 26109.3% | — |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$72.1M | -$56.0M | -$33.0M | -$59.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · 2 Falling Stocks Call Traders Are Targeting Today
2026-09-24 · Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder
2026-09-24 · Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
2026-09-23 · Top Premarket Gainers
2026-09-10 · Vistagen to Present at Psych Congress 2026
2026-08-14 · Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
2026-08-06 · Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
2026-08-04 · SRX Global Acquires Stake in Vistagen Therapeutics
2026-08-04 · Top Premarket Gainers
Price (daily)
Full chart · RSI · MACD · patterns